MedTrace Logo

Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury

NCT00990028 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-10-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether rosuvastatin could alter the immunological response after head injury by modulating TNF-alpha,IL6,IL-1.

Conditions

  • Head Injury

Interventions

DRUG

Rosuvastatin

20 mg oral, for 10 days

DRUG

Placebo

20 mg vehicle

Sponsors & Collaborators

  • Hospital Central "Dr. Ignacio Morones Prieto"

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Universidad Autonoma de San Luis Potosí

    lead OTHER

Principal Investigators

  • Antonio Gordillo-Moscoso, PhD · Clinical Epidemiology UASLP

  • Martin Sanchez-Aguilar, MSc · Clinical epidemiology UASLP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-07-31
Completion
2011-08-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00990028 on ClinicalTrials.gov